Next Article in Journal
Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B
Next Article in Special Issue
Botulinum Toxin Type A as a Therapeutic Agent against Headache and Related Disorders
Previous Article in Journal
Effects of Melittin Treatment in Cholangitis and Biliary Fibrosis in a Model of Xenobiotic-Induced Cholestasis in Mice
Previous Article in Special Issue
Botulinum Toxin for Neuropathic Pain: A Review of the Literature
Article Menu

Export Article

Open AccessReview
Toxins 2015, 7(9), 3388-3404; doi:10.3390/toxins7093388

The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee Pain

1
Centre for Musculoskeletal Studies, School of Surgery M424, the University of Western, 35 Stirling Highway, Nedlands, WA 6009, Australia
2
Faculty of Medicine, Dentistry and Health Science, the University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Bahman Jabbari
Received: 2 June 2015 / Revised: 12 August 2015 / Accepted: 17 August 2015 / Published: 25 August 2015
(This article belongs to the Collection Botulinum Toxins on Human Pain)
View Full-Text   |   Download PDF [1105 KB, uploaded 25 August 2015]   |  

Abstract

Anterior knee pain is a highly prevalent condition affecting largely young to middle aged adults. Symptoms can recur in more than two thirds of cases, often resulting in activity limitation and reduced participation in employment and recreational pursuits. Persistent anterior knee pain is difficult to treat and many individuals eventually consider a surgical intervention. Evidence for long term benefit of most conservative treatments or surgical approaches is currently lacking. Injection of Botulinum toxin type A to the distal region of vastus lateralis muscle causes a short term functional “denervation” which moderates the influence of vastus lateralis muscle on the knee extensor mechanism and increases the relative contribution of the vastus medialis muscle. Initial data suggest that, compared with other interventions for anterior knee pain, Botulinum toxin type A injection, in combination with an active exercise programme, can lead to sustained relief of symptoms, reduced health care utilisation and increased activity participation. The procedure is less invasive than surgical intervention, relatively easy to perform, and is time- and cost-effective. Further studies, including larger randomized placebo-controlled trials, are required to confirm the effectiveness of Botulinum toxin type A injection for anterior knee pain and to elaborate the possible mechanisms underpinning pain and symptom relief. View Full-Text
Keywords: anterior knee pain; muscle imbalance; botulinum toxin type A anterior knee pain; muscle imbalance; botulinum toxin type A
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Singer, B.J.; Silbert, B.I.; Silbert, P.L.; Singer, K.P. The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee Pain. Toxins 2015, 7, 3388-3404.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top